Every 8-K that Aligos Therapeutics, Inc. (ALGS) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow ALGS and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full ALGS filings page.
Aligos Therapeutics reported second quarter 2026 results and detailed progress in its hepatitis B pipeline. The company strengthened its balance sheet with a $25 million upfront payment from an exclusive Greater China license for pevifoscorvir sodium and a $3 million milestone tied to IND approval for ALG-170675.
Pevifoscorvir sodium received Breakthrough Therapy Designation in China, complementing U.S. Fast Track status, and the Phase 2 B-SUPREME trial completed enrollment with 131 HBeAg+ and 114 HBeAg- participants, with topline data expected in late Q3 2027. ALG-170675, a next-generation antisense oligonucleotide, will enter Phase 1 studies in China funded by partner Amoytop, while Aligos retains ex-Greater China rights.
Cash, cash equivalents and investments were $30.4 million as of June 30, 2026, excluding the $25 million upfront received in July, and are expected to fund operations into the fourth quarter of 2026. For Q2, Aligos reported a net loss of $1.5 million, compared with $15.9 million a year earlier, with R&D expenses rising to $24.1 million as B-SUPREME advanced.
Aligos Therapeutics, Inc. reported the results of its Annual Meeting of Stockholders and an amendment to its 2020 Employee Stock Purchase Plan (ESPP). Stockholders approved adding 500,000 shares for issuance under the Amended ESPP and removing its automatic “evergreen” annual share increase feature, fixing the total share reserve.
Two Class III directors, Bridget Martell and Carole Nuechterlein, were elected to serve until the 2029 annual meeting. Stockholders ratified Ernst & Young LLP as independent auditor for the fiscal year ending December 31, 2026. They also approved, on an advisory basis, the compensation of named executive officers and chose to hold future advisory “say-on-pay” votes every year. The record date for the meeting covered 5,388,223 shares of voting common stock outstanding.
Aligos Therapeutics, Inc. reported first quarter 2026 results with revenue of $2.83M and a net loss of $23.0M, or $2.21 per share. Cash, cash equivalents and investments totaled $54.9M as of March 31, 2026 and are expected to fund operations into the fourth quarter of 2026.
During the quarter, pevifoscorvir sodium for chronic HBV infection received Fast Track Designation from the FDA and delivered a positive first interim analysis in the Phase 2 B-SUPREME study, with study continuation and good tolerability. Aligos also signed an exclusive Greater China license with Amoytop that includes a $25M upfront payment and up to $420M in milestones plus tiered royalties.
Aligos Therapeutics, Inc. entered a regional license agreement with Xiamen Amoytop Biotech for its investigational Hepatitis B therapy pevifoscorvir sodium. Amoytop receives exclusive rights to develop, manufacture and commercialize the drug in mainland China, Taiwan, Hong Kong and Macau.
Aligos will receive an upfront cash payment of $25 million, and may earn up to $420 million in additional development, regulatory and commercial milestones, plus tiered high single-digit royalties on net sales. Amoytop will fund and lead development, regulatory work, manufacturing and commercialization in the territory, while both parties share certain data and intellectual property under perpetual, largely royalty-free cross-licenses.
Aligos Therapeutics filed an update highlighting interim Phase 2 data and a key regulatory milestone for its hepatitis B drug candidate pevifoscorvir sodium. An independent safety board reviewed early results from the B-SUPREME study and recommended continuing the trial while increasing the sample size in the HBeAg- cohort to strengthen statistical power, noting that futility criteria were not met. The company remains blinded to individual patient data. Enrollment has reached 74 participants in the HBeAg- cohort and 103 in the HBeAg+ cohort, with about 200 patients planned overall, and topline data targeted for 2027. The FDA has granted Fast Track Designation to pevifoscorvir sodium, based on Phase 1 data showing it was well tolerated with promising reductions in multiple viral markers, potentially supporting a faster and more interactive regulatory review path for this chronic hepatitis B program.
Aligos Therapeutics reported recent pipeline progress and sharply improved 2025 financial results. Cash, cash equivalents and investments were $77.8 million as of December 31, 2025, which the company expects will fund planned operations into the third quarter of 2026.
Net loss narrowed to $19.9 million for the fourth quarter of 2025, compared with $82.2 million a year earlier. For the full year 2025, net loss fell to $24.2 million from $131.2 million, helped by $60.2 million of income from the change in fair value of 2023 common warrants.
In its HBV portfolio, the Phase 2 B-SUPREME study of pevifoscorvir sodium completed planned enrollment of 60 HBeAg- participants, with HBeAg+ enrollment ongoing and topline data expected in 2027. ALG-170675 was advanced into IND-enabling studies with partner Amoytop, while preclinical data for ALG-055009 showed additional weight loss when combined with incretin therapies. Aligos also added an Executive Vice President, Chief Commercial Officer to build commercial capabilities.
Aligos Therapeutics, Inc. announced that its Board of Directors appointed Nikhil Aneja as the company’s Principal Accounting Officer, effective immediately. He replaces Lesley Ann Calhoun in that specific role, while she continues as Executive Vice President, Chief Operating Officer and Chief Financial Officer.
Mr. Aneja, age 49, has been Aligos’s Vice President, Finance since February 2024. His background includes senior finance and controller positions at CareDx, Blade Therapeutics and Global Blood Therapeutics, and he is a Certified Public Accountant with a Bachelor of Commerce from the University of Delhi.
Aligos Therapeutics (ALGS) reported it furnished a press release via an 8-K under Item 2.02 (Results of Operations and Financial Condition) on November 6, 2025. The press release is attached as Exhibit 99.1 and is incorporated by reference in the report.
The company states the information under Item 2.02 and Exhibit 99.1 is being furnished and not deemed filed for purposes of Section 18 of the Exchange Act, and it will not be incorporated into other filings unless expressly referenced. Aligos’ common stock trades on the Nasdaq Capital Market under the symbol ALGS.
Aligos Therapeutics (Nasdaq:ALGS) filed an 8-K disclosing results of its June 25, 2025 Annual Meeting.
- Authorized share increase: voting common stock rises from 20 million to 100 million; non-voting common stock from 0.8 million to 15.8 million (Item 5.03).
- Equity plan expansion: 2020 Incentive Award Plan enlarged by 1,000,000 shares (Item 5.02).
- All proposals passed with c.~87% support; three Class II directors re-elected and Ernst & Young ratified as auditor (Item 5.07).
- Shares outstanding on record date: 5,314,801.
The amendments give management broad capacity to issue new equity for financing or compensation, but materially raise dilution risk for existing holders. No financial results were reported.